Form 4: Bionano Genomics COO Acquires Stock Options

Mark Oldakowski, Chief Operating Officer of Bionano Genomics, acquired stock options on March 14, 2025, according to a Form 4 filing with the SEC.

Summary

• A Form 4 filing with the SEC indicates that Mark Oldakowski, the Chief Operating Officer of Bionano Genomics, acquired stock options on March 14, 2025.
• The stock options grant the right to buy 6,966 shares of Bionano Genomics common stock at an exercise price of $3.47 per share.
• The options vest monthly over 48 months, beginning one month after the vesting commencement date, and will be fully vested and exercisable on the four-year anniversary of that date.
• The expiration date for these options is March 13, 2035.
• Following the transaction, Oldakowski directly owns 6,966 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to stock options, suggesting standard executive compensation practices. It doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of stock options by a key executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The acquisition of stock options by the COO could potentially align his interests with those of the shareholders, as the value of the options is tied to the company's stock performance.

Key Dates